Insider Stock Trading History of Mcenany Patrick J


The following table details the trading activities (stock purchases, stock sales, and stock option exercises) reported to the Securities and Exchange Commission (SEC) by insider Mcenany Patrick J since year 2005. The trader's CIK number is 929985. At the time of this reporting, Mcenany Patrick J is the President and CEO of Catalyst Pharmaceutical Partners, Inc. . (stock ticker symbol CPRX). See this page for all insider trading activities at Catalyst Pharmaceutical Partners, Inc. .

Note that in the past MCENANY PATRICK J also reported insider trading activities as an insider of the following companies:
Stock purchases, sales, and option exercises reported by insider Mcenany Patrick J since 2005.
  Trade Date   Symbol Company Name (Issuer) Trade Type     Shares       Price ($)   Value ($)
2017-09-05 CPRX Catalyst Pharmaceutical Partners, Inc. Buy 20,000 2.58 51,560
2017-05-22 CPRX Catalyst Pharmaceutical Partners, Inc. Option Ex 31,250 1.04 32,500
2016-11-17 CPRX Catalyst Pharmaceutical Partners, Inc. Option Ex 26,667 .00 0
2016-06-14 CPRX Catalyst Pharmaceutical Partners, Inc. Buy 105,300 .65 68,550
2016-04-26 CPRX Catalyst Pharmaceutical Partners, Inc. Buy 50,000 .65 32,450
2015-12-28 CPRX Catalyst Pharmaceutical Partners, Inc. Buy 25,000 2.39 59,724
2015-12-07 CPRX Catalyst Pharmaceutical Partners, Inc. Option Ex 26,666 .00 0
2015-10-29 CPRX Catalyst Pharmaceutical Partners, Inc. Option Ex 75,000 1.09 81,750
2015-10-01 CPRX Catalyst Pharmaceutical Partners, Inc. Buy 10,000 2.81 28,100
2015-04-27 CPRX Catalyst Pharmaceutical Partners, Inc. Buy 5,000 3.79 18,950
2015-01-08 CPRX Catalyst Pharmaceutical Partners, Inc. Buy 50,000 2.79 139,750
2014-10-02 CPRX Catalyst Pharmaceutical Partners, Inc. Option Ex 150,000 .90 135,000
2014-05-21 CPRX Catalyst Pharmaceutical Partners, Inc. Buy 25,000 1.89 47,225
2014-02-07 CPRX Catalyst Pharmaceutical Partners, Inc. Buy 25,000 1.82 45,500
2013-10-21 CPRX Catalyst Pharmaceutical Partners, Inc. Buy 50,000 1.59 79,750
2013-02-19 CPRX Catalyst Pharmaceutical Partners, Inc. Buy 50,000 .46 23,000
2012-12-17 CPRX Catalyst Pharmaceutical Partners, Inc. Buy 100,000 .45 44,500
2012-11-15 CPRX Catalyst Pharmaceutical Partners, Inc. Buy 100,000 .42 42,000
2012-07-03 CPRX Catalyst Pharmaceutical Partners, Inc. Buy 700 .54 374
2012-07-02 CPRX Catalyst Pharmaceutical Partners, Inc. Buy 30,500 .54 16,409
2012-05-30 CPRX Catalyst Pharmaceutical Partners, Inc. Buy 10,000 .58 5,790
2012-05-24 CPRX Catalyst Pharmaceutical Partners, Inc. Buy 31,250 .80 25,000
2012-02-14 CPRX Catalyst Pharmaceutical Partners, Inc. Buy 25,000 1.12 28,125
2011-12-14 CPRX Catalyst Pharmaceutical Partners, Inc. Buy 10,000 1.06 10,580
2010-07-07 CPRX Catalyst Pharmaceutical Partners, Inc. Buy 5,751 .92 5,273
2010-07-06 CPRX Catalyst Pharmaceutical Partners, Inc. Buy 200 .92 184
2010-06-15 CPRX Catalyst Pharmaceutical Partners, Inc. Buy 9,359 1.04 9,733
2009-05-19 KOOL Thermogenesis Corp Buy 25,000 .58 14,499
2009-05-08 KOOL Thermogenesis Corp Buy 25,000 .53 13,250
2009-03-06 CPRX Catalyst Pharmaceutical Partners, Inc. Buy 5,000 1.55 7,750
2008-12-30 CPRX Catalyst Pharmaceutical Partners, Inc. Buy 1,417 1.69 2,394
2008-12-17 CPRX Catalyst Pharmaceutical Partners, Inc. Buy 2,500 1.80 4,500
2008-12-08 CPRX Catalyst Pharmaceutical Partners, Inc. Buy 2,500 2.05 5,125
2008-09-24 CPRX Catalyst Pharmaceutical Partners, Inc. Buy 11,900 2.37 28,250
2008-09-18 CPRX Catalyst Pharmaceutical Partners, Inc. Buy 400 2.50 1,000
2008-09-17 CPRX Catalyst Pharmaceutical Partners, Inc. Buy 2,001 2.52 5,052
2008-01-28 CPRX Catalyst Pharmaceutical Partners, Inc. Buy 25,100 3.05 76,555
2008-01-28 CPRX Catalyst Pharmaceutical Partners, Inc. Buy 25,100 3.05 76,555
2007-07-17 KOOL Thermogenesis Corp Option Ex 10,000 1.81 18,100
2007-01-29 KOOL Thermogenesis Corp Option Ex 4,000 2.34 9,360

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Mcenany Patrick J (President and CEO of Catalyst Pharmaceutical Partners, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.